Previous 10 | Next 10 |
KemPharm, Inc. (KMPH) Q4 2021 Earnings Conference Call March 30, 2022, 05:00 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors Travis Mickle - President and CEO LaDuane Clifton - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Presentation Operator...
KemPharm press release (NASDAQ:KMPH): Q4 GAAP EPS of -$0.08. Revenue of $2.6M (+8.3% Y/Y). Total cash, cash equivalents and long-term investments was $127.8 million as of December 31, 2021. Shares +3%. For further details see: KemPharm GAAP EPS of -$0.08, revenue of $2.6M
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing and commercializing therapeutics targeting rare central nervous system (CNS) and n...
KemPharm (NASDAQ:KMPH) is scheduled to announce Q4 earnings results on Wednesday, March 30th, after market close. The consensus EPS Estimate is -$0.07 (+93.5% Y/Y) and the consensus Revenue Estimate is $2.23M (-7.1% Y/Y). For further details see: KemPharm Q4 Earnings Preview
CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtua...
KemPharm (NASDAQ:KMPH) said full data from Phase 1 trial showed higher doses of serdexmethylphenidate (SDX) were generally well-tolerated and produced targeted pharmacodynamic effects, that may benefit to treat idiopathic hypersomnia and other sleep disorders. SDX is the active...
Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep disorders Upcoming anticipated development milestones for KP1077 include: IND ...
KemPharm (NASDAQ:KMPH), a maker of prodrugs, announced on Wednesday that the company would receive a $1.975 million fee from Corium Inc. following the U.S. approval of ADLARITY, a treatment for dementia of Alzheimer's type. The U.S. Food and Drug Administration (FDA) cleared Coriu...
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement CELEBRATION, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), a specialty pharmaceutical company focuse...
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022, 5:00 p.m. ET CELEBRATION, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and developmen...
News, Short Squeeze, Breakout and More Instantly...
CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Org...
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission...
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:3...